Key result
The 2007 ESH-ESC guidelines classify ~25% more hypertensive patients as high CV risk versus 2003 criteria.
Why the study?
Does the inclusion of metabolic syndrome in the 2007 ESH-ESC guidelines increase the proportion of hypertensive patients classified as high or very high cardiovascular risk compared to the 2003 guidelines?
Cross-Sectional (n=720)
No
Does the inclusion of metabolic syndrome in the 2007 ESH-ESC guidelines increase the proportion of hypertensive patients classified as high or very high cardiovascular risk compared to the 2003 guidelines?
Absolute Event Rate: 73.9% vs 48.9%
Incorporating metabolic syndrome into risk stratification per the 2007 ESH-ESC guidelines significantly increases the proportion of hypertensive patients identified as high or very high cardiovascular risk.
MS inclusion reclassifies more hypertensives to high/very-high risk; leaves open whether updated stratification improves outcome prediction.
OBJECTIVE: To investigate the influence of metabolic syndrome (MS) on risk stratification and ulterior classification in hypertensive patients at entry into a hypertension unit by comparing the criteria of ESH-ESC 2003 and 2007 guidelines. METHODS: 720 consecutive patients attending a hospital-located hypertension unit were included in the study. They were classified with or without MS according to the ATP-III 2005 report. Patients underwent repeated office BP measurements and routine blood/urine examinations. In addition ultrasensitive CRP (uCRP), echocardiogram, fasting insulin, urinary albumin excretion were determined and HOMA index was calculated. RESULTS: The prevalence of MS was 58.8 %. Abdominal obesity and fasting glucose were the most prevalent components of MS, and HDL-cholesterol the least prevalent. MS group had higher levels of LDL-cholesterol and higher prevalence of left ventricular hypertrophy and microalbuminuria. Patients with MS also presented a significant elevation in uCRP, fasting insulin and HOMA. BP was controlled in 55.6%. When we applied the 2003 guideline, 48.9% patients showed a high or very high added cardiovascular risk. With the applications of the 2007 guide the prevalence of this two categories reach 73.9%. CONCLUSIONS: A significant difference in the risk pattern distribution is found when MS is considered in risk stratification in our hypertensive population. The accompanying increase in the levels of other cardiovascular risk factors and in the prevalence of target organ damage justifies the global intervention on cardiovascular risk recommended by 2007 ESH-ESC guidelines.
No takes yet. Share an insight, caveat, or question.
Martell et al. (2010) conducted a cross-sectional in Hypertension (n=720). 2007 ESH-ESC guidelines vs. 2003 ESH-ESC guidelines was evaluated on High or very high added cardiovascular risk classification. Application of the 2007 ESH-ESC guidelines classified 73.9% of hypertensive patients as having high or very high cardiovascular risk, compared to 48.9% using the 2003 guidelines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: